Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4175.30 +1.6% SILVER 57.30 +2.5% COPPER 6.57 −1.3% OIL 97.57 +2.6% PALLADIUM 1133.75 +3.4% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.09 −0.9% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.180 +5.9% EVI 0.520 +4.0% ADZ 0.125 +0.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.245 +0.0% BAU 0.180 −5.3% TECT 1.71 +3.0% TOM 0.140 +3.7% GOLD 4175.30 +1.6% SILVER 57.30 +2.5% COPPER 6.57 −1.3% OIL 97.57 +2.6% PALLADIUM 1133.75 +3.4% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.09 −0.9% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.180 +5.9% EVI 0.520 +4.0% ADZ 0.125 +0.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.245 +0.0% BAU 0.180 −5.3% TECT 1.71 +3.0% TOM 0.140 +3.7%
Earnings

Cipher Pharmaceuticals Schedules Q4 & Fiscal 2025 Earnings Release and Conference Call

By The Northwire Desk — AI Analysis Mar 04, 2026 · 17:00 CPH · 14.86 CIPHER PHARMACEUTICALS INC.
CPH · Price

Executive Summary

  • Cipher Pharmaceuticals announced it will release its Q4 2025 and fiscal‑2025 financial results after market close on Thursday, March 12 2026.
  • A conference call to discuss the results and corporate developments is scheduled for Friday, March 13 2026 at 8:30 a.m. ET.
  • Call details (dial‑in numbers, replay code, webcast link) were provided for investors and analysts.

Key Details

  • Release Timing: Financial results will be posted after market close on Thursday, March 12 2026.
  • Conference Call:
  • Date: Friday, March 13 2026
  • Time: 8:30 a.m. ET
  • Dial‑in Numbers: 416‑945‑7677 or 888‑699‑1199 (U.S.)
  • Replay Access: 289‑819‑1450 or 888‑660‑6345, Code 29916#, expires March 20 2026.
  • Webcast URL: https://app.webinar.net/G7lE687Woew
  • Company Background (boilerplate removed): Cipher Pharmaceuticals is a specialty pharma company with products marketed in Canada, the U.S., and South America.

Notable Quotes

(No executive quotes were included in this release.)

Read the original news release →

More from CIPHER PHARMACEUTICALS INC.

May 07, 2026 · 17:00

Cipher Goes Debt-Free and Boasts $71M in Dry Powder, But Stagnant Sales Raise the Bar for Deal-Driven Growth

Earnings May 01, 2026 · 07:00

Cipher Pharmaceuticals NCIB Announcement

Other Mar 12, 2026 · 17:00

Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings

Earnings Jan 28, 2026 · 17:51

Cipher Pharmaceuticals gets Health Canada NDS review

Regulatory Jan 28, 2026 · 08:30

Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba(TM) (Spinosad)

Regulatory Nov 06, 2025 · 17:00

Cipher Pharmaceuticals Reports Third Quarter 2025 Results

Earnings